Crucell Strengthens its Vaccine Sales in the UK with a Dedicated
Marketing and Sales Organization
(Thomson Reuters ONE) - Leiden, The Netherlands (September 30, 2009) - Dutch biopharmacompany Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX)today announced the launch of its own dedicated marketing and salesorganization in the United Kingdom by acquiring an experienced team,to further strengthen its vaccine sales position in one of thelargest vaccine markets in Europe.Crucell's UK team will market and sell Crucell's travel vaccinesEpaxal® (aluminum-free hepatitis A vaccine), Vivotif® (oral typhoidfever vaccine) and Dukoral® (oral vaccine against cholera andtravelers' diarrhea), as well as its registered virosomal adjuvantedinfluenza vaccine Inflexal® V. Distribution of the travel vaccineswill start immediately and distribution of the influenza vaccineswill start in 2010. Crucell has identified the UK as a high-potentialmarket that deserves extra attention."In markets where Crucell has established its own dedicated marketingand sales organization, we have been able to increase our marketshare substantially and cost efficiently. Building a dedicatedorganization fully focused on selling our travel and respiratoryvaccines in the UK will enable us to penetrate this market much moreeffectively and is therefore a logical step in expanding our currentreach" said Ronald Brus, Crucell's Chief Executive Officer.Previously, Crucell distributed its travel vaccines through theUK-based company MASTA Ltd, and influenza vaccines through SanofiPasteur MSD. With the establishment of its own dedicated sales team,Crucell will be able to focus on expanding market share for Crucell'stravel and respiratory vaccines in the UK. This development is inline with Crucell's strategic focus on expanding sales in carefullyselected markets.About CrucellCrucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is aglobal biopharmaceutical company focused on research development,production and marketing of vaccines, proteins and antibodies thatprevent and/or treat infectious diseases. Its vaccines are sold inpublic and private markets worldwide. Crucell's core portfolioincludes a vaccine against hepatitis B, a fully-liquid vaccineagainst five important childhood diseases and a virosome-adjuvantedvaccine against influenza. Crucell also markets travel vaccines, suchas the only oral anti-typhoid vaccine, an oral cholera vaccine andthe only aluminum-free hepatitis A vaccine on the market. The Companyhas a broad development pipeline, with several product candidatesbased on its unique PER.C6® production technology. The Companylicenses its PER.C6® technology and other technologies to thebiopharmaceutical industry. Important partners and licensees includeDSM Biologics, sanofi-aventis, Novartis, Wyeth, GSK, CSL and Merck &Co. Crucell is headquartered in Leiden, the Netherlands, withsubsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the U.S.The Company employs over 1000 people. For more information, pleasevisit www.crucell.com.Forward-looking statementsThis press release contains forward-looking statements that involveinherent risks and uncertainties. We have identified certainimportant factors that may cause actual results to differ materiallyfrom those contained in such forward-looking statements. Forinformation relating to these factors please refer to our Form 20-F,as filed with the U.S. Securities and Exchange Commission on April22, 2009, in the section entitled 'Risk Factors'. The Companyprepares its financial statements under International FinancialReporting Standards (IFRS).For further information please contact:Crucell N.V.Oya YavuzVice PresidentCorporate Communications & Investor RelationsTel. +31-(0)71-519 7064ir(at)crucell.comwww.crucell.comhttp://hugin.info/132631/R/1344744/322548.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 30.09.2009 - 07:45 Uhr
Sprache: Deutsch
News-ID 6384
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 244 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Crucell Strengthens its Vaccine Sales in the UK with a Dedicated
Marketing and Sales Organization"
steht unter der journalistisch-redaktionellen Verantwortung von
Crucell N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
